Opendata, web and dolomites

MEDAS

MedAS: a Machine learning enabled Clinical Decision Support System to prevent prescription errors and improve patient safety

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEDAS project word cloud

Explore the words cloud of the MEDAS project. It provides you a very rough idea of what is the project "MEDAS" about.

deploy    burden    accidentally    trials    theme    died    financial    8m    safety    accuracy    alerts    roi    adverse    outliers    missed    commercial    electronic    first    realising    simply    facilities    clinical    constantly    generation    started    market    team    identifies    time    founders    machine    rates    22    21    revenues    fatal    failed    primary    patient    medical    israel    enter    error    economic    decided    medaware    total    care    solid    public    1m    decision    prescribing    2012    big    usa    learning    cdss    8b    found    analytics    enabled    80    nine    precise    utilizes    medicines    action    otherwise    healthcare    innovative    proven    country    issue    physician    outcomes    representing    retrospective    health    5b    prototype    errors    solutions       events    effectiveness    annual    dramatically    proof    estimate    2018    boy    2024    generate    perspectives       51    depending    medas    save       platform    intend    data    pull    statistical    drug    list    preventable    managed    reaching    completely    reducing    alerting    became    opportunity    prescription    medication    algorithms    feasibility    seize    wrong   

Project "MEDAS" data sheet

The following table provides information about the project.

Coordinator
MEDAWARE LTD 

Organization address
address: 10 ZARHIN ALEXANDER
city: RAANANA
postcode: 4366238
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.medaware.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDAWARE LTD IL (RAANANA) coordinator 50˙000.00

Map

 Project objective

Medication errors are the most common cause of adverse events in medication practice, although they are preventable. Only in Europe, prescription error rates range from 7.5% to 9.1% of the total managed medicines, representing a major public health issue, as some of those can even be fatal. They also represent a great economic burden to healthcare systems, with annual costs reaching €4.5B to €21.8B, depending on the country. MedAware’s founders decided to take action on the theme in 2012, when they found out that a nine-year-old boy died simply because his primary care physician accidentally selected the wrong drug, on his electronic prescribing pull-down list. By realising that current solutions completely failed to save this boy, the team started developing several proof-of-concept algorithms that became our first prototype and then MedAS (MedAware Alerting System). MedAS is an innovative patient-specific Clinical Decision Support System, that identifies and alerts on prescription errors in real-time, and with greater than 80% accuracy. It utilizes big-data analytics and advanced machine learning to identify statistical outliers and to generate precise alerts that would otherwise be missed by existing CDSS. MedAS’s effectiveness has already been proven both in retrospective trials and in real medical facilities in Israel and the USA: we improved patient safety, outcomes, and experience while dramatically reducing healthcare costs. Enabled by our next generation technology and given MedAS’s unique capabilities, we now intend to build a solid technology platform and to deploy it to the European market. The main objective of the feasibility study is to assess MedAS from technical, commercial and financial perspectives. We will seize the opportunity to enter the constantly growing CDSS market (€51.8M in Europe by 2018) with our novel technology and platform, and estimate revenues of €22.1M by 2024, with a ROI of 8.9

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

WIMUACT (2017)

TECHNOLOGY FOR THE IMPROVEMENT OF SPORTS PERFORMANCE IN NON-PROFESSIONAL CONTEXTS

Read More  

Revault (2015)

Revault - world´s first wearable private cloud. Securely sync and access your files from anywhere without an internet connection.

Read More  

Enterprise BIM (2017)

Enterprise BIM digitization platform feasibility verification

Read More